Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH)
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease
(NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically …

The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a
leading cause of cancer-related death worldwide. In the United States, HCC is the ninth …

Background & Aims There have been many studies of the effects of non-alcoholic fatty liver
disease (NAFLD) and the risk of cardiovascular disease (CVD), but these have produced …